MedTrace Logo

Low-dose Rituximab Regimens in Chinese Adult Patients With Immune Thrombocytopenia

NCT01719692 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-02-11

No results posted yet for this study

Summary

A comparative study with rituximab (100 mg weekly for 4 weeks and 375mg/m2 for once) shows low dose rituximab may be a useful alternative therapy in patients with ITP.The aim of this study is to compare the efficacy and tolerability of two different regimens of low doses rituximab for the treatment of adult patients with ITP.

Conditions

  • Immune Thrombocytopenic Purpura

Interventions

DRUG

Rituximab

Sponsors & Collaborators

  • Langfang Traditional Chinese Medicine Hospital

    collaborator UNKNOWN

  • Henan Cancer Hospital

    collaborator OTHER_GOV

  • The Second Affiliated Hospital of Kunming Medical University

    collaborator OTHER

  • Institute of Hematology & Blood Diseases Hospital, China

    lead OTHER

Principal Investigators

  • RENCHI YANG, Dr · Hospital of Blood disease

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2015-10-31
Completion
2016-02-29

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01719692 on ClinicalTrials.gov